GH
GHC.F Garofalo Health Care S.p.A
- Market cap
- EUR 447M
- P/E
- 24.1x
- P/B
- 1.34x
- ROE
- 8.8%
- Dividend yield
- 1.70%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is GHC.F undervalued?
Graham numberGHC.F trades 19.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Garofalo Health Care S.p.A fundamental analysis
No fundamental analysis for Garofalo Health Care S.p.A yet.
Garofalo Health Care S.p.A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Garofalo Health Care S.p.A
Garofalo Health Care S.p.A., together with its subsidiaries, operates healthcare clinics in Italy. It operates through Hospital and Social/Dependency Care segments. The company offers high-complexity surgery, medium- and low-complexity surgery, emergency surgery, medicine, clinical and interventional cardiology, and extended and intensive care units, as well as motor, neurological, cardiac, and nutritional rehabilitation. It also operates centers for patients in coma and per…
Full company profileGarofalo Health Care S.p.A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Garofalo Health Care S.p.A annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 124M | 152M | 154M | 196M | 207M | 278M | 315M | 366M | 468M | 485M | 526M |
| Gross Profit | 57.1M | 73.2M | 70.3M | 90.6M | 90.0M | 121M | 136M | 316M | 398M | 410M | 316M |
| Operating Income | 11.5M | 21.0M | 20.4M | 21.7M | 16.4M | 28.4M | 32.1M | 46.5M | 54.8M | 55.1M | 68.6M |
| EBITDA | - | 26.5M | 25.4M | 31.0M | 27.1M | 43.7M | 49.9M | 60.7M | 69.9M | 72.7M | 84.1M |
| Net Income | 5.49M | 13.2M | 13.6M | 13.1M | 11.8M | 18.8M | 21.4M | 20.8M | 21.7M | 23.4M | 30.4M |
| EPS | - | 0.16 | 0.17 | 0.16 | 0.14 | 0.21 | 0.24 | 0.23 | 0.25 | 0.26 | 0.34 |
| Balance Sheet | |||||||||||
| Total Assets | 171M | 216M | 289M | 432M | 460M | 627M | 646M | 796M | 850M | 860M | 908M |
| Total Liabilities | 91.7M | 114M | 103M | 240M | 257M | 366M | 367M | 495M | 517M | 510M | 551M |
| Shareholders' Equity | 76.7M | 95.3M | 179M | 192M | 203M | 260M | 279M | 299M | 322M | 339M | 346M |
| Cash & Short-term Investments | 19.2M | 22.6M | 92.3M | 27.8M | 24.8M | 41.2M | 31.4M | 22.7M | 26.7M | 19.9M | 12.2M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 12.4M | 26.8M | 18.5M | 18.9M | 23.0M | 36.3M | 43.9M | 50.0M | 35.0M | 49.0M | 48.1M |
| Capital Expenditure | 5.25M | 2.53M | 9.03M | 8.81M | 11.0M | 23.2M | 13.8M | 17.2M | 21.6M | 33.5M | 41.4M |
| Free Cash Flow | - | 29.2M | 9.38M | 9.70M | 10.8M | 11.6M | 28.9M | 32.9M | 13.4M | 15.5M | 6.66M |
| Ratios | |||||||||||
| ROE | 7.2% | 13.8% | 7.6% | 6.8% | 5.8% | 7.2% | 7.7% | 7.0% | 6.7% | 6.9% | 8.8% |
| ROA | 3.2% | 6.1% | 4.7% | 3.0% | 2.6% | 3.0% | 3.3% | 2.6% | 2.6% | 2.7% | 3.3% |
| Net Profit Margin | 4.4% | 8.7% | 8.8% | 6.7% | 5.7% | 6.8% | 6.8% | 5.7% | 4.6% | 4.8% | 5.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Garofalo Health Care S.p.A dividends
- Dividend yield
- 1.70%
- Forward dividend
- 0.09 EUR
- Payout ratio
- 32.4%
- Ex-dividend date
- May 18, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 7.59M | 0.09 | 32.4% |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | EUR 750K | 0.01 | 5.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Garofalo Health Care S.p.A
- Insiders 68.28%
- Institutions 10.30%
- Public & others 21.42%
- Shares outstanding 88.4M
- Free float 77.1M
Garofalo Health Care S.p.A company profile
- Company name
- Garofalo Health Care S.p.A
- Ticker
- GHC.F
- ISIN
- IT0005345233
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 2,839
- Fiscal year end
- December
- Address
- Piazzale Belle Arti, n.6, Rome, RM, Italy, 00196
- Phone
- 39 06 684891
- Website
- garofalohealthcare.com
About Garofalo Health Care S.p.A
Garofalo Health Care S.p.A., together with its subsidiaries, operates healthcare clinics in Italy. It operates through Hospital and Social/Dependency Care segments. The company offers high-complexity surgery, medium- and low-complexity surgery, emergency surgery, medicine, clinical and interventional cardiology, and extended and intensive care units, as well as motor, neurological, cardiac, and nutritional rehabilitation. It also operates centers for patients in coma and persistent vegetative states; and psychiatric and diagnostic centers. The company was founded in 2000 and is based in Rome, Italy. Garofalo Health Care S.p.A. is a subsidiary of Larama 98 S.p.A.
Garofalo Health Care S.p.A management
3- Attorney Maria Laura GarofaloCEO & Director · born 1963
- Ms. Claudia GarofaloExecutive Director · born 1985
- Mr. Guido Dalla Rosa PratiExecutive Director